PDD与PTD方案对多发性骨髓瘤患者的疗效及IL-6水平的影响比较  

Comparison of the Effects of PDD and PTD and IL-6 Levels in Patients with Multiple Myeloma

作　　者：谢玮[1] 庞缨[1] 叶絮[1] 冯莹[1] 李澄宇[1] 

机构地区：[1]广州医科大学第二附属医院血液内科,广东广州510260

出　　处：《河北医学》2017年第6期882-886,共5页Hebei Medicine

基　　金：2013年建设中医药强省立项资助科研课题;(编号:20131262)

摘　　要：目的:研究对比PDD(硼替佐米+脂质体阿霉素+地塞米松)与PTD(硼替佐米+吡柔比星+地塞米松)方案对多发性骨髓瘤患者的疗效及IL-6水平的影响。方法:选取2012年1月至2017年1月我院收治的初治MM患者38例。根据治疗方案的不同分为PDD组19例,PTD组19例。分别治疗4周后观察两组临床疗效、治疗前后血清IL-6水平、M蛋白、瘤细胞数、β_2微球蛋白等情况以及不良反应发生情况。结果:PDD组治疗总缓解率(sCR+CR)为31.58%(6/19),与PTD组的5.26%(2/19)比较,差异有统计学意义(P<0.05)。治疗后两组血清IL-6水平均低于治疗前,而PDD组又低于PTD组,且均有显著性差异(均P<0.05)。治疗后PDD组M蛋白、瘤细胞数以及β_2微球蛋白水平均低于PTD组,且均有显著性差异(均P<0.05)。PDD组与PTD组血液学不良反应发生率差异无统计学意义(P>0.05),但PDD组在脱发及心脏毒性方面的发生率比PTD组明显减少。结论:PDD方案治疗MM的临床疗效更佳,且能有效改善患者血清IL-6、M蛋白、瘤细胞数、β_2微球蛋白水平,安全性较好,值得临床推广应用。Objective：To study the contrast PDD （Bortezomib ＋ liposome adriamycin ＋ dexamethasone） with PTD （Bortezomib ＋ pirarubicin ＋ dexamethasone） solutions in patients with multiple myeloma curative effect and the influence of the level of IL-6.Methods： From January 2012 to January 2017, Selection of 38 cases of patients with MM.According to the different methods of treatment were divided into PDD group （19 cases）, PTD group 19 cases.4 weeks after treatment, respectively observed before and after treatment of the two groups of clinical curative effect, before and after treatment serum levels of IL-6,M protein,tumor cells and β2-microglobulin and adverse reactions occured.Results： The PDD treatment group total remissio rate（sCR＋CR） was 31.58% （6/19）, compared with PTD group 5.26% （2/19）, there＇＇s significant difference （P 0.05）,but the incidence of alopecia and cardiac toxicity in PDD group was significantly lower than PTD group.Conclusion：The PDD therapy in the treatment of MM had better clinical curative effect, and can effectively improve the patients＇＇ serum level of IL-6,M protein,tumor cells and β2-microglobulin, better security, worthy of clinical popularization and application.

关 键 词：多发性骨髓瘤 硼替佐米 脂质体阿霉素 地塞米松 白细胞介素-6 

分 类 号：R733.3[医药卫生—肿瘤]